Skip to main content
星昊医药 logo

星昊医药 — Investor Relations & Filings

Ticker · 920017 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 417 across all filing types
Latest filing 2025-01-13 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920017

About 星昊医药

https://www.sunho.com.cn/

Beijing Sunho Pharmaceutical Co., Ltd. is a technology-driven enterprise specializing in the research, development, manufacturing, and commercialization of advanced pharmaceutical preparations. The company focuses on high-barrier drug delivery systems, including sustained-release, controlled-release, and complex injection technologies. Its core business encompasses the production of a diverse portfolio of chemical drugs and biological products, alongside comprehensive Contract Development and Manufacturing Organization (CDMO) services. Sunho Pharmaceutical operates modern, GMP-compliant production facilities designed to support the entire lifecycle of drug development, from pilot-scale testing to large-scale commercial manufacturing. By leveraging its proprietary formulation platforms, the company provides integrated solutions for complex dosage forms, catering to both domestic and international pharmaceutical markets.

Recent filings

Filing Released Lang Actions
变更部分募集资金用途公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the change in the use of previously raised funds from a share issuance by Beijing Xinghao Pharmaceutical Co., Ltd. It includes specifics about the original fundraising, the amounts raised, the projects funded, and the reasons for reallocating the funds among different projects. It also contains information about the decision-making process, approvals by the board, supervisory board, and independent directors, and confirms that the changes do not harm shareholders' interests. The document is not a full financial report, audit report, or earnings release, but rather an update on capital usage and financing activities related to the company's fundraising. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length and detail confirm it is not a mere announcement of a report (RPA) or a regulatory filing (RNS).
2025-01-13 Chinese
监事辞职公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a company supervisor (监事) from Beijing Xinghao Pharmaceutical Co., Ltd. It details the resignation date, reasons, and the impact on the company's board composition and operations. There is no financial data, no mention of financial results, no regulatory filings about financial performance, no voting results, no capital changes, and no legal proceedings. The document is clearly about a change in the company's board or senior management structure. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused solely on this personnel change, confirming it is not a full report or announcement of a report publication.
2025-01-09 Chinese
关于完成工商变更登记及公司章程备案并取得营业执照的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the completion of industrial and commercial registration changes and the filing of the company's articles of association, including obtaining a new business license. It details changes in registered capital and confirms that other registration items remain unchanged. The document is short (1027 characters) and serves as a formal notification of corporate registration updates following shareholder meeting resolutions. It does not contain financial statements, audit information, or detailed management reports. It is not a report itself but an announcement of corporate changes and filings. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2025-01-05 Chinese
关于孙公司参与第十批全国药品集中采购拟中标的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Beijing Xinghao Pharmaceutical Co., Ltd. regarding its subsidiary's participation and proposed winning bid in the 10th batch of national centralized drug procurement. It details the product involved, pricing, expected impact on the company, and risk warnings. The document is relatively short (1394 characters) and focuses on a specific procurement event and its implications rather than providing comprehensive financial data or a full report. There is no indication of it being an annual or interim report, earnings release, or other detailed financial filing. It is an announcement about a business event related to procurement and sales impact, fitting best under general regulatory announcements. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2024-12-11 Chinese
回购股份注销完成暨股份变动公告
Transaction in Own Shares Classification · 100% confidence The document is a formal announcement from Beijing Xinghao Pharmaceutical Co., Ltd. regarding the completion of share repurchase cancellation and the resulting changes in shareholding structure. It details the number of shares repurchased and cancelled, the impact on total shares outstanding, and subsequent administrative steps. The document includes specific dates, share quantities, and references to official confirmations. It does not contain financial statements or detailed financial analysis but is focused on the company's share repurchase and capital structure update. Therefore, it fits the category of a Transaction in Own Shares (POS) filing, which covers share buybacks and related capital changes.
2024-12-09 Chinese
股权激励计划限制性股票解除限售公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement from Beijing Xinghao Pharmaceutical Co., Ltd. regarding the lifting of restrictions on certain restricted stocks under the company's equity incentive plan. It details the number of shares being unlocked, the shareholders involved, reasons for unlocking, and the updated share capital structure. The document is a formal disclosure about changes in share restrictions and share tradability, which is related to share transactions by insiders or management but not about their personal share dealings. It is not a financial report, earnings release, or management discussion. It is also not a proxy, AGM material, or legal proceeding. The content fits best with a Transaction in Own Shares (POS) category, as it concerns changes in share restrictions and availability for trading, which is a type of capital change related to shares held by insiders or management. The document length is about 5190 characters, sufficient for a detailed announcement rather than a brief notice. Therefore, the classification is POS with high confidence.
2024-12-09 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.